BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Health Canada: GlaxoSmithKline (GSK) Issues Warning on Pulmonary Arterial Hypertension Drug


7/13/2012 8:46:57 AM

GlaxoSmithKline has written to doctors telling them not to use lung drug Volibris in patients with idiopathic pulmonary fibrosis, Canadian regulator Health Canada said on Thursday. Volibris is the Canadian and European brand name for Gilead Sciences' Letairis, which British group GSK sells outside the United States. The drug is approved to treat pulmonary arterial hypertension, a rare and potentially fatal disorder of arteries in the lungs which also affects the heart. But it may also be used by some doctors on an "off label" basis for idiopathic pulmonary fibrosis (IPF).

Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES